Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 8/20 | 0.85 |
| ▸ | HIF1A | Q16665 | 8/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.81 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.81 |
| ▸ | PGR | P06401 | 3/20 | 0.81 |
| ▸ | TSHR | P16473 | 2/20 | 0.81 |
| ▸ | AR | P10275 | 2/20 | 0.81 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.81 |
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.81 |
| ▸ | APEX1 | P27695 | 1/20 | 0.81 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.81 |
| ▸ | IKBKB | O14920 | 1/20 | 0.81 |
| ▸ | CHUK | O15111 | 1/20 | 0.81 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.81 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.81 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.81 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxibetasol SCHEMBL140220 | 1.00 | NR3C1 (0.85) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 | |
| Doxibetasol SCHEMBL140221 | 1.00 | NR3C1 (0.85) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 | |
| Doxibetasol SCHEMBL11328088 | 1.00 | NR3C1 (0.85) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 | |
| Doxibetasol SCHEMBL11885535 | 1.00 | NR3C1 (0.85) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 | |
| Doxibetasol SCHEMBL13754704 | 1.00 | NR3C1 (0.85) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 | |
| Doxibetasol SCHEMBL19026488 | 0.96 | NR3C1 (0.80) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 | |
| Doxibetasol SCHEMBL19026536 | 0.96 | NR3C1 (0.80) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 | |
| SCHEMBL18379414 | 0.92 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 | |
| SCHEMBL19764184 | 0.92 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 | |
| SCHEMBL19308807 | 0.92 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230099074-A1 | ANTIBODY DRUG CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS | MERCK SHARP & DOHME LLC (US) | 2023-03-30 | — | — | US | disclosed |
| US-20200164085-A1 | ANTIBODY DRUG CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS | MERCK SHARP & DOHME LLC | 2020-05-28 | — | — | US | disclosed |
| US-10550190-B2 | Phosphate based linkers for intracellular delivery of drug conjugates | MERCK SHARP & DOHME CORP. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20170182181-A1 | PHOSPHATE BASED LINKERS FOR INTRACELLULAR DELIVERY OF DRUG CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-7645747-B2 | Improved pharmacokinetic properties, oral bioavailability; side effect reduction | GILEAD SCIENCES, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | CANNIZZARO CARINA | 2009-10-01 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7432261-B2 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-4269778-A | REACTING AN ACETONE OR DIMETHYLFORMAMIDE SUSPENSION OF THE SULFONATE DERIVATIVE OBTAINED FROM REACTING THE ALCOHOL WITH A SULFONATING AGENT WITH A THIO CARBOXYLATE | SIPSY (FR) | 1981-05-26 | — | — | US | disclosed |
| US-3984544-A | Retinoic acid esters of steroids of the pregnane series, their use in the treatment of acne and pharmaceutical formulations useful therefor | SCHERING CORPORATION (US) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200164085-A1 | ANTIBODY DRUG CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS | CD44, FCGR2A, TNF | NR3C1 3860/4885HIF1A 1730/4885CYP3A4 3539/4885 |
| US-20170182181-A1 | PHOSPHATE BASED LINKERS FOR INTRACELLULAR DELIVERY OF DRUG CONJUGATES | CD47, PLPBP, CHERP | NR3C1 4286/4885HIF1A 3738/4885CYP3A4 3250/4885 |
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | PHOSPHO1, TNF, PTGES | NR3C1 310/4885HIF1A 1199/4885CYP3A4 1894/4885 |
| US-20230099074-A1 | ANTIBODY DRUG CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS | CD44, FCGR2A, TNF | NR3C1 3860/4885HIF1A 1730/4885CYP3A4 3539/4885 |
| US-10550190-B2 | Phosphate based linkers for intracellular delivery of drug conjugates | CD47, PLPBP, CHERP | NR3C1 4286/4885HIF1A 3738/4885CYP3A4 3250/4885 |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | NR3C1 2696/4885HIF1A 1722/4885CYP3A4 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.